Our Promise
Our Purpose
“Make Premium Healthcare Affordable”, ensuring your health is not a barrier to unlocking your true potential.
Our Dream
Our Key Milestones
1939 – J. L. Morison Son & Jones (Ceylon) was incorporated as a trading post of J. L. Morison Son & Jones (UK)
1959 – Ventured into pharmaceutical manufacturing with the inauguration of MSJ Industries (Ceylon) Ltd, our first manufacturing facility at Mutwal Aluthmawatha, becoming one of the pioneers of generic pharmaceutical manufacturing in Sri Lanka
2013 – The diversified conglomerate Hemas Holdings PLC acquired the majority shareholding of the company, making Morison a subsidiary of the Hemas Group
2017 – The corporate brand name of J.L. Morison Son & Jones (Ceylon) PLC was re-branded as Morison PLC, with a logo that is simple and contemporary
2020 – Morison unveiled Sri Lanka’s first and largest oral solid and liquid dosage pharmaceutical manufacturing facility that complies with WHO GMP and EU GMP quality standards, in Pitipana Homagama
2021 – Morison PLC became a limited liability company with Hemas Holdings owning more than 90% of its shareholding, and is now known as Morison Ltd
2021 – Introduced “EmpaMor” (Empagliflozin 10mg 25mg), the first ever locally manufactured SGLT2 (Sodium-Glucose Co-Transported-2), an oral medication to treat Type-2 Diabetes, at a significant price benefit from competition.
2022 – Launched commercial operations from our new state-of-the-art manufacturing facility in Homagama on 26th May 2022.
2023 – Morison’s entry into the branded pharma segment showed good traction, with EmpaMor becoming Number Two across all Empagliflozin brands in Sri Lanka. EmpaMor became number one in volumes across all Empagliflozin brands in Sri Lanka, within just two years from launch – IQVIA 2023 Q1, Q3 and Q4.
2024 – LMD recognized Morison as the Pharmaceutical Sector winner in LMD’s Most Respected Entities in Sri Lanka in 2024
2025 – In February 2025, Morison entered the cardiovascular therapeutic space, with the theme of “Touching More Hearts” unveiling RivoMor (Rivaroxaban), CilniMor (Cilnidipine), and BisoMor (Bisoprolol) – three promising advanced therapies manufactured to world-class standards. Rivaroxaban and Cilnidipine are being manufactured in Sri Lanka for the first time.
Board of Directors
Driven by experience and expertise, our leadership team inspires us to surpass our goals and deliver stakeholder value.
Murtaza Esufally
Murtaza Esufally is the Non-Executive Chairman of Morison Limited. Mr. Murtaza Esufally counts more than 30 years of experience in senior management levels. He holds a master’s degree in business administration from the Melbourne business school of the university of Melbourne, Bachelor of law degree from the university of Essex, UK, Barrister at Law from Lincolns Inn attorney-at-Law of the supreme court of Sri Lanka. He also served on several subsidiary boards of the Hemas Group.